MX2024008557A - Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos. - Google Patents

Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos.

Info

Publication number
MX2024008557A
MX2024008557A MX2024008557A MX2024008557A MX2024008557A MX 2024008557 A MX2024008557 A MX 2024008557A MX 2024008557 A MX2024008557 A MX 2024008557A MX 2024008557 A MX2024008557 A MX 2024008557A MX 2024008557 A MX2024008557 A MX 2024008557A
Authority
MX
Mexico
Prior art keywords
upadacitinib
administering
effects
drug interactions
adverse drug
Prior art date
Application number
MX2024008557A
Other languages
English (en)
Spanish (es)
Inventor
Mohamed-Eslam F Mohamed
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2024008557A publication Critical patent/MX2024008557A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024008557A 2022-01-13 2023-01-13 Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos. MX2024008557A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263299324P 2022-01-13 2022-01-13
US202263320149P 2022-03-15 2022-03-15
PCT/US2023/060648 WO2023137440A2 (en) 2022-01-13 2023-01-13 Method of administering upadacitinib to avoid adverse drug interactions and effects

Publications (1)

Publication Number Publication Date
MX2024008557A true MX2024008557A (es) 2024-09-11

Family

ID=87279802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008557A MX2024008557A (es) 2022-01-13 2023-01-13 Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos.

Country Status (8)

Country Link
US (1) US20230233555A1 (https=)
EP (1) EP4463161A4 (https=)
JP (1) JP2025502266A (https=)
KR (1) KR20240148324A (https=)
AU (1) AU2023206381A1 (https=)
CA (1) CA3246767A1 (https=)
MX (1) MX2024008557A (https=)
WO (1) WO2023137440A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570664B2 (en) 2015-10-16 2026-03-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11564922B2 (en) * 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AU2018230500B2 (en) * 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
US10857144B2 (en) * 2017-05-16 2020-12-08 Bow River LLC Methods of treatment

Also Published As

Publication number Publication date
WO2023137440A3 (en) 2023-10-05
AU2023206381A1 (en) 2024-07-25
EP4463161A2 (en) 2024-11-20
EP4463161A4 (en) 2026-01-14
CA3246767A1 (en) 2023-07-20
JP2025502266A (ja) 2025-01-24
US20230233555A1 (en) 2023-07-27
KR20240148324A (ko) 2024-10-11
WO2023137440A2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
MX2024008557A (es) Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos.
MX2022009044A (es) Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
Wickramaratneb Serotonergic anxiolytics and treatment of depression
Agarwal et al. Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature
Kavand et al. Cutaneous manifestations of graft‐versus‐host disease: role of the dermatologist
EP1196167A1 (en) Method of reducing neuronal injury or apoptosis
KR20140117244A (ko) 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
CN1395484A (zh) 用于治疗牛皮癣的物质
Ishida et al. Comparison of outcomes for pediatric patients with acute myeloid leukemia in remission and undergoing allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens based on either intravenous busulfan or total body irradiation: a report from the Japanese Society for Hematopoietic Cell Transplantation
US11673965B2 (en) Method of treating metastatic triple negative breast cancer with radiotherapy combined with phosphatidyl inositol-3 kinase delta/gamma inhibitors and anti-PD-1 antibodies
JP2019059748A (ja) 移植患者における移植片対宿主病の治療
WO2022241151A3 (en) Chimeric antigen receptor t cell therapy
WO2022026900A3 (en) Nk receptor antagonists for cancer patients
Li et al. Neurod1 modulates opioid antinociceptive tolerance via two distinct mechanisms
ZA202400228B (en) Combination therapies for treatment of liver diseases
MX2024009972A (es) Terapias combinadas para el tratamiento del cancer que comprenden un conjugado de farmaco anticuerpo b7-h4.
CR20220531A (es) Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
CN120713908A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
WO2023141609A3 (en) Treatment of inflammatory disorders
CN103417971A (zh) 二肽基肽酶抑制剂和b族维生素的药物组合物及用途
MX2024005374A (es) Metodos para tratar la enfermedad de celulas falciformes con voxelotor.
CN116983407A (zh) 一种治疗膝关节炎的新一代干细胞治疗剂及其制备工艺
WO2022178340A3 (en) Pharmaceutical compositions comprising ranpirnase
IL300809A (en) Cellular preparation for the treatment of diseases and method of use
WO2007011960A3 (en) Methods and agents to treat autoimmune diseases